Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fufang Xiaoying Keli (Compound Xiaoying Granules) is a Traditional Chinese Medicine (TCM) compound formulation primarily utilized for the treatment of thyroid disorders such as goiter and thyroid nodules. Developed as a hospital preparation (notably by the China-Japan Friendship Hospital in Beijing), it is composed of several herbal ingredients including *Prunella vulgaris* (Xiaokuicao), *Sargassum* (Haizao), *Laminaria* (Kunbu), *Scrophularia* (Xuanshen), and *Concha Ostreae* (Muli). The formulation is designed to resolve phlegm, soften hard masses, and clear heat, addressing the TCM pathogenesis of Qi stagnation and phlegm coagulation in the thyroid. Clinically, it is used to reduce the size of benign thyroid nodules and alleviate symptoms associated with thyroid enlargement. While its precise molecular mechanisms are complex due to its multi-component nature, research suggests it may modulate thyroid hormone signaling and exert anti-inflammatory and anti-proliferative effects on thyroid tissue.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fufang xiaoying keli.